UCB announces BRIVIACT (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients Read more
Novartis announces FDA approval of Gilenya as the first disease-modifying therapy for pediatric relapsing multiple sclerosis Read more
miRagen Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides Read more
Sylentis Announces the Clinical Results of Tivanisiran for the Treatment of Dry Eye Syndrome Read more
Bioniz Therapeutics Announces Positive Phase 1b Clinical Study Results for Investigational Agent BNZ-1 Read more